GlassScriptPhysician profile
Sherry Xie
NPI 1891711636
$6,522.90
in general payments reported to CMS, 2019-2025
30 companies · $557 in 2025
The $557 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,357 · 2020: $448 · 2021: $101 · 2022: $1,064 · 2023: $2,101 · 2024: $895 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,552.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $748.73 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $553.73 | 2019-2022 | |
| Gilead Sciences, INC. | $544.06 | 2019 | |
| Amgen INC. | $536.71 | 2019-2025 | Repatha, Evenity, Otezla |
| Lilly USA, LLC | $515.52 | 2019-2025 | Mounjaro, Zepbound |
| Teva Pharmaceuticals USA, INC. | $484.30 | 2019-2025 | Austedo Xr, Austedo Xr |
| Glaxosmithkline, LLC. | $474.15 | 2022-2024 | Arexvy, Trelegy Ellipta |
| Abbvie INC. | $466.45 | 2020-2024 | Ubrelvy, Qulipta |
| Pfizer INC. | $369.90 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.64 | 2019-2024 | Jardiance |
| Cmp Pharma, INC. | $237.31 | 2023 | Norliqva |
| Janssen Pharmaceuticals, INC | $191.34 | 2022-2023 | Xarelto |
| Esperion Therapeutics, INC. | $124.99 | 2024 | Nexlizet, Nexletol |
| Aimmune Therapeutics, INC. | $124.98 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $124.97 | 2023 | Rexulti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $122.16 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $121.83 | 2025 | Zoryve |
| Redhill Biopharma INC. | $116.67 | 2022 | |
| Cequr Corporation | $105.99 | 2023 | Cequr Simplicity |
| Dexcom, INC. | $59.28 | 2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $49.42 | 2022-2025 | Gardasil 9, Capvaxive |
| Amarin Pharma, INC. | $41.99 | 2019-2021 | |
| Exact Sciences Corporation | $33.88 | 2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $25.19 | 2019 | |
| Allergan, INC. | $24.28 | 2020 | |
| Shield Therapeutics INC | $21.40 | 2023 | Accrufer |
| Sanofi Pasteur INC. | $19.53 | 2019 | |
| Alk-Abello, INC | $16.05 | 2024 | Ragwitek, Odactra, Grastek |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.98 | 2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $14.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Xie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.